UNSPSC 51433931: Clevidipine butyrate

This classification denotes a calcium channel blocker with the molecular formula C21H23Cl2NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19O2GP3B7Q, chemically known as 3,5-pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, methyl (1-oxobutoxy)methyl ester but more generally known as clevidipine, which bears US NIH Compound Identifier 153994. European Medicines Agency schedules Clevidipine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06655MIG.

UNSPSC 51433931 Clevidipine butyrate is a Commodity code that captures emergency cardiovascular medications and specialized pharmaceutical products procured by state and local health systems, fire rescue departments, and pharmacy benefit programs. State and local governments buying under this code source advanced life support medications, generic pharmaceuticals, and over-the-counter products through a mix of direct municipal purchases, cooperative purchasing alliances, and state health agency initiatives. The issuing bodies include city fire rescue operations (Tampa Fire Rescue), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing entities (Minnesota Multistate Cooperative Purchasing Alliance, serving state and local facilities). Scope ranges from emergency medication procurement for first-response operations to systematic pharmaceutical supply agreements supporting state employee health plans and institutional healthcare networks.

Recent activity spans Florida, Texas, and a multistate cooperative footprint anchored in Minnesota and Oregon. The City of Tampa's Purchasing Department issued IFB 26-P-00188 in April 2026 for Advanced Life Support Medications—370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials—with a response deadline of April 8, 2026 and an estimated contract value of $40,000, including a 5 percent bid discount for Small Local Business Enterprise participation. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to assess vendor capability for direct-to-manufacturer prescription programs serving the state's pharmacy benefit operations. The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 via MMCAP in January 2026 for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, establishing multi-award contracts effective July 1, 2026, requiring compliance with FDA standards, cGMP certification, Drug Supply Chain Security Act compliance, and delivery through authorized wholesalers including AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson.